GIBBSTOWN, N.J.-The Novagen brand of EMD Chemicals, a subsidiary of Merck KGaA, Darmstadt, Germany, announced that it has obtained a license from Luminex Corp. to develop immunoassays for the xMAP Technology platform. EMD/Merck is engaged in the development, manufacture and distribution of a broad array of research tools used for life science research and will create multiplex immunoassays using xMAP Technology to meet the evolving needs of drug discovery and cell signaling researchers.

 "The advantages of multiplex protein analysis are well established," says Lisa Johnson, VP of corporate development with EMD. "The Luminex xMAP platform has been instrumental in broadening the adoption of multiplex analysis."